Detalhe da pesquisa
1.
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study.
Hepatology
; 78(4): 1223-1239, 2023 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37162151
2.
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH.
J Hepatol
; 77(5): 1399-1409, 2022 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-35779659
3.
Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production.
Gastroenterology
; 148(2): 403-14.e7, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25305505
4.
Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection.
Hepatology
; 62(4): 1013-23, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26118427
5.
Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
Hepatology
; 59(5): 1706-14, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24375768
6.
Truncated CXCL10 is associated with failure to achieve spontaneous clearance of acute hepatitis C infection.
Hepatology
; 60(2): 487-96, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24668726
7.
Cyclophilin inhibition as potential therapy for liver diseases.
J Hepatol
; 61(5): 1166-74, 2014 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25048953
8.
The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance.
Antimicrob Agents Chemother
; 58(6): 3327-34, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24687498
9.
Circulating chemokine (C-X-C Motif) receptor 5(+) CD4(+) T cells benefit hepatitis B e antigen seroconversion through IL-21 in patients with chronic hepatitis B virus infection.
Hepatology
; 58(4): 1277-86, 2013 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-23703545
10.
Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial.
Nat Med
; 29(2): 392-400, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36797481
11.
High serum IL-21 levels after 12 weeks of antiviral therapy predict HBeAg seroconversion in chronic hepatitis B.
J Hepatol
; 56(4): 775-81, 2012 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-22173154
12.
CD8(+) T cell control of hepatitis B virus replication: direct comparison between cytolytic and noncytolytic functions.
J Immunol
; 184(1): 287-95, 2010 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19949099
13.
Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells.
Hepatology
; 52(3): 875-85, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20593455
14.
Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients.
Hepatology
; 52(5): 1611-20, 2010 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-20931556
15.
Telbivudine versus lamivudine in patients with chronic hepatitis B.
N Engl J Med
; 357(25): 2576-88, 2007 Dec 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-18094378
16.
2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B.
Gastroenterology
; 136(2): 486-95, 2009 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-19027013
17.
Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.
J Hepatol
; 51(1): 11-20, 2009 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19345439
18.
Early viraemia clearance during antiviral therapy of chronic hepatitis C improves dendritic cell functions.
Clin Immunol
; 131(3): 415-25, 2009 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-19303818
19.
Programmed death 1 expression during antiviral treatment of chronic hepatitis B: Impact of hepatitis B e-antigen seroconversion.
Hepatology
; 48(3): 759-69, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18697210
20.
APOBEC and iNOS are not the main intracellular effectors of IFN-gamma-mediated inactivation of Hepatitis B virus replication.
Antiviral Res
; 78(3): 260-7, 2008 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-18313151